Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Topical beremagene geperpavec
BIOLOGICAL
2 trials
Sponsors
Krystal Biotech, Inc.
Conditions
Dominant Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa
Phase 1
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
Completed
NCT03536143
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa
Start: 2018-05-06
End: 2019-11-01
Updated: 2023-01-31
Phase 3
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
Completed
NCT04491604
Krystal Biotech, Inc.
Dominant Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Start: 2020-08-17
End: 2022-01-14
Updated: 2023-02-17
Related Papers
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
2025-04-12
5 citations
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
New England Journal of Medicine
2022-12-14
165 citations
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
2022-03-28
101 citations